Abstract

BackgroundBaricitinib is a potent, selective JAK1 and JAK2 inhibitor. Baricitinib has been investigated in phase II and phase III studies of active patients with rheumatoid arthritis (RA). who showed an...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
SAT0138 The effectiveness of adalimumab concomitant with disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis
N Ishiguro ... K Terabe
Annals of the Rheumatic Diseases | VOL. 71
N Ishiguro, et. al.N Ishiguro ... K Terabe
01 Jun 2013
Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
Guanglei Yu ... Manabu Ohyama
Journal of the American Academy of Dermatology | VOL. 85
Guanglei Yu, et. al.Guanglei Yu ... Manabu Ohyama
16 Jun 2021
FRI0210 Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent
M.-W So ... C.-K Lee
Annals of the Rheumatic Diseases | VOL. 72
M.-W So, et. al.M.-W So ... C.-K Lee
01 Jun 2013
Influence of Anti-TNF and Disease Modifying Antirheumatic Drugs Therapy on Pulmonary Forced Vital Capacity Associated to Ankylosing Spondylitis: A 2-Year Follow-Up Observational Study
Viviana Díaz-González ... María Guadalupe Zavala-Cerna
Journal of Immunology Research | VOL. 2015
Viviana Díaz-González, et. al.Viviana Díaz-González ... María Guadalupe Zavala-Cerna
01 Jan 2015
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations
Myrto Kostopoulou ... Antonis Fanouriakis
Annals of the Rheumatic Diseases | VOL. -
Myrto Kostopoulou, et. al.Myrto Kostopoulou ... Antonis Fanouriakis
22 May 2024
View more papers